对以下内容的勘误：日本晚期前列腺癌患者使用阿帕鲁胺后的皮疹：3期SPARTAN和TITAN研究及1期开放标签研究的综合分析
Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.
作者信息
Uemura Hiroji, Koroki Yosuke, Iwaki Yuki, Imanaka Keiichiro, Kambara Takeshi, Lopez-Gitlitz Angela, Smith Andressa, Uemura Hirotsugu
机构信息
Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.
Medical Affairs, Janssen Pharmaceutical K.K., Tokyo, Japan.
出版信息
BMC Urol. 2020 Oct 22;20(1):166. doi: 10.1186/s12894-020-00739-7.
Abstract
An amendment to this paper has been published and can be accessed via the original article.
摘要
本文的一个修订版本已发表，可通过原始文章获取。
相似文献
1
Correction to: Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.对以下内容的勘误：日本晚期前列腺癌患者使用阿帕鲁胺后的皮疹：3期SPARTAN和TITAN研究及1期开放标签研究的综合分析
BMC Urol. 2020 Oct 22;20(1):166. doi: 10.1186/s12894-020-00739-7.
2
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.在日本晚期前列腺癌患者中应用阿帕鲁胺后的皮疹：SPARTAN 和 TITAN 研究的 3 期综合分析和 1 期开放标签研究。
BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0.
3
Concomitant use of oral anticoagulants in patients with advanced prostate cancer receiving apalutamide: A post-hoc analysis of TITAN and SPARTAN studies.在接受阿帕鲁胺治疗的晚期前列腺癌患者中口服抗凝剂的联合使用：TITAN和SPARTAN研究的事后分析
Am J Cancer Res. 2022 Jan 15;12(1):445-450. eCollection 2022.
4
Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.在Apa-RP研究中，皮疹管理指南对接受阿帕鲁胺治疗的高危局限性前列腺癌患者的影响。
Prostate Cancer Prostatic Dis. 2024 Jul 5. doi: 10.1038/s41391-024-00858-4.
5
An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer.一项开放标签、I 期研究评估雄激素受体拮抗剂阿帕鲁胺在日本转移性去势抵抗性前列腺癌患者中的疗效。
Int J Clin Oncol. 2019 Dec;24(12):1596-1604. doi: 10.1007/s10147-019-01526-7. Epub 2019 Aug 24.
6
Apalutamide: A new agent in the management of prostate cancer.阿帕鲁胺：前列腺癌治疗的新药物。
J Oncol Pharm Pract. 2019 Dec;25(8):1968-1978. doi: 10.1177/1078155219864424. Epub 2019 Jul 30.
7
Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.阿帕鲁胺治疗去势抵抗性前列腺癌：来自临床试验的证据。
Ther Adv Urol. 2018 Nov 11;10(12):445-454. doi: 10.1177/1756287218811450. eCollection 2018 Dec.
8
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.阿帕他胺治疗转移性去势敏感性前列腺癌（TITAN）患者的健康相关生活质量：一项随机、安慰剂对照、III 期研究。
Lancet Oncol. 2019 Nov;20(11):1518-1530. doi: 10.1016/S1470-2045(19)30620-5. Epub 2019 Sep 29.
9
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.阿帕鲁胺治疗与前列腺癌无转移生存。
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
10
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.阿帕鲁胺治疗转移性去势敏感性前列腺癌。
N Engl J Med. 2019 Jul 4;381(1):13-24. doi: 10.1056/NEJMoa1903307. Epub 2019 May 31.
本文引用的文献
1
Skin rash following Administration of Apalutamide in Japanese patients with Advanced Prostate Cancer: an integrated analysis of the phase 3 SPARTAN and TITAN studies and a phase 1 open-label study.在日本晚期前列腺癌患者中应用阿帕鲁胺后的皮疹：SPARTAN 和 TITAN 研究的 3 期综合分析和 1 期开放标签研究。
BMC Urol. 2020 Sep 2;20(1):139. doi: 10.1186/s12894-020-00689-0.
Zotero 插件